Quadruple therapy should be second-line treatment for Helicobacter pylori infection

2000 ◽  
pp. 631-635 ◽  
Author(s):  
A. Axon
Keyword(s):  
Helicobacter Pylori ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Second Line ◽  
Quadruple Therapy

Second-Line Treatment for Helicobacter pylori Infection: 10-day Moxifloxacin-Based Triple Therapy versus 2-week Quadruple Therapy

Helicobacter ◽  
2007 ◽  
Vol 12 (6) ◽  
pp. 623-628 ◽  
Author(s):  
Jung Mook Kang ◽  
Nayoung Kim ◽  
Dong Ho Lee ◽  
Young Soo Park ◽  
Yu Rim Kim ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Second Line ◽  
Quadruple Therapy

44 P Quadruple therapy as second-line treatment for helicobacter pylori infection: 1-week versus 2-week regimens

2002 ◽  
Vol 34 ◽  
pp. A21
Author(s):  
F. Iacopini ◽  
O.A. Paoluzi ◽  
A. Consolazio ◽  
G. Occhigrossi ◽  
R. Pica ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Second Line ◽  
Quadruple Therapy

scholarly journals Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection

2022 ◽  
Vol 12 (1) ◽  
pp. 56
Author(s):  
Jeemyoung Kim ◽  
Eun Jeong Gong ◽  
Myeongsook Seo ◽  
Hyun Il Seo ◽  
Jong Kyu Park ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Eradication Therapy ◽  
Helicobacter Pylori Infection ◽  
Adverse Event Rate ◽  
Line Treatment ◽  
Second Line ◽  
Current Smoking ◽  
Quadruple Therapy ◽  
Standard Triple Therapy ◽  
H Pylori

Bismuth quadruple therapy (BQT) is an effective treatment for Helicobacter pylori infection. However, frequent dosing schedules of BQT regimen often compromise drug adherence and may affect treatment outcomes. This retrospective study aimed to investigate the efficacy of twice-daily BQT compared to that of four times a day therapy. From August 2018 to November 2020, adult patients who failed first-line standard triple therapy and underwent BQT were eligible. Patients were categorized into two groups according to dosing schedule: (i) the BQT group (n = 213) who received standard BQT administered four times a day; and (ii) the BQTb group (n = 141) who received proton pump inhibitor, bismuth 600 mg, metronidazole 500 mg, and tetracycline 1 g twice a day. The eradication rate did not differ between the BQT (92.5%) and the BQTb groups (90.1%) (p = 0.441). Adherence and adverse event rate were similar between the two groups. Multivariate analysis showed that current smoking was associated with eradication failure; however, dosing frequency was not associated with the efficacy of eradication therapy. This study suggested that twice a day BQT is as effective as four times a day therapy for second-line treatment of H. pylori infection.

Su1696 Efficacy of Second-Line Treatment for Helicobacter pylori Infection: Moxifloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy

2012 ◽  
Vol 142 (5) ◽  
pp. S-483-S-484 ◽  
Author(s):  
Kwang Hyun Chung ◽  
Dong Ho Lee ◽  
Nayoung Kim ◽  
Cheol Min Shin ◽  
Jin Hyeok Hwang ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Second Line ◽  
Quadruple Therapy
Sign in / Sign up

Export Citation Format

Share Document